vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock, up previously from $40.00.
vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.
vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.
An Alzheimer's Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here? [Yahoo! Finance]